Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2025 07:00 ET | Source: BioStem Technologies, Inc.

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology
January 02, 2025 07:00 ET | Source: BioStem Technologies, Inc.

BioStem Technologies CEO to Present at Biotech Showcase 2025

BioStem Technologies CEO to Present at Biotech Showcase 2025
November 25, 2024 07:00 ET | Source: BioStem Technologies, Inc.

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
November 20, 2024 07:00 ET | Source: BioStem Technologies, Inc.

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
November 12, 2024 07:29 ET | Source: BioStem Technologies, Inc.

BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million

BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
October 29, 2024 07:00 ET | Source: BioStem Technologies, Inc.

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All MAC Regions
October 28, 2024 13:58 ET | Source: BioStem Technologies, Inc.

BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 17, 2024 07:00 ET | Source: BioStem Technologies, Inc.

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
October 15, 2024 07:00 ET | Source: BioStem Technologies, Inc.

BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions

BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
October 02, 2024 07:00 ET | Source: BioStem Technologies, Inc.

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right